<DOC>
	<DOCNO>NCT01499667</DOCNO>
	<brief_summary>This study evaluate disease control different length treatment transition natalizumab fingolimod .</brief_summary>
	<brief_title>Disease Control Safety Patients With Relapsing Remitting Multiple Sclerosis ( RRMS ) Switching From Natalizumab Fingolimod</brief_title>
	<detailed_description>Patient screen , sign informed consent visit 1 , 2nd visit , patient receive baseline infusion Natalizumub subsequently randomize one 3 treatment arm . At randomization visit , Washout Phase start , eligible patient randomize 1:1:1 one three treatment group : - 8-week washout ( 8 week treatment ) follow 24 week treatment fingolimod , - 12-week washout ( 8 week treatment 4 week placebo ) follow 20 week treatment fingolimod , - 16-week washout ( 8 week treatment 8 week placebo ) follow 16 week treatment fingolimod .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients must : Have relapse remit multiple sclerosis Have treatment natalizumab least 6 month prior screen discontinuation option . Patients : History chronic immune disease Crohn 's disease Certain cancer Uncontrolled diabetes Certain eye disorder Negative varicellazoster virus IgG antibodies Certain hepatic condition Low white blood cell count On certain immunosuppressive medication heart medication Resting heart rate le 45 bpm . Certain heart condition certain lung condition Inability undergo MRI scan Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Relapsing remit multiple sclerosis</keyword>
	<keyword>multiple sclerosis ( MS )</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>health outcome</keyword>
	<keyword>fingolimod</keyword>
	<keyword>disease control</keyword>
	<keyword>MRI</keyword>
</DOC>